Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma
Crossref DOI link: https://doi.org/10.1007/s00280-015-2854-0
Published Online: 2015-09-02
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tian, Jing
Shang, Ming
Shi, Sheng-Bin
Han, Yong
Xu, Jun
Text and Data Mining valid from 2015-09-02